Parexel Consulting Corporate VP Alberto Grignolo On Conducting Clinical Trials In China, India And Asia: An Interview With PharmAsia News
This article was originally published in PharmAsia News
Parexel Consulting Corporate VP Alberto Grignolo recently spoke with PharmAsia News about Asia's evolving clinical trial environment - including the launch of U.S. FDA offices in Asia and the prospect of multinational companies conducting Phase I trials in India. Parexel works with life sciences companies to create clinical development strategies as well as Good Clinical Practices and Good Manufacturing Practices compliance.
You may also be interested in...
Sweeping Changes In India’s Clinical Trial Laws Could Allow Phase I MNC Studies Under Certain Circumstances
MUMBAI - Conducting clinical trials in India may get a little easier for multinational drug companies. That is because the much-awaited amendments to the contentious "Schedule Y" of India's Drug and Cosmetics Act have moved one step forward
U.S. and China are close to finalizing plans to open U.S. FDA offices in China, and FDA could have "boots on the ground" as early as September, according to Murray Lumpkin, FDA's deputy commissioner for international and special Programs
Part of Baxter's response to its heparin contamination fiasco has been to bring its scientists together to imagine ways counterfeiters could infiltrate its supply chain and how they would be countered.